Indonesia Energy Corporation Limited vs Revolution Medicines Inc. Common Stock — how do they compare? Indonesia Energy Corporation Limited trades at $2.74 (market cap $43.24M), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 932.5× Indonesia Energy Corporation Limited's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| INDO | RVMD | |
|---|---|---|
Market Cap | $43.24M | $40.32B |
Volume | 116,953 | 4,855,734 |
Sector | Energy | Health |
52-Week High | $6.74 | $221.15 |
52-Week Low | $2.49 | $47.50 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $38.18M | $37.02B |
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.74, down 1.08% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $5.10 million on $2.01 million revenue in 2025, with negative profit margins and cash flow from operations. Recent news highlights progress on the K-29 well drilling and upcoming investor presentations.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with persistent losses and negative cash flow. The stock's outlook hinges on successful production from new wells, but execution risks and weak fundamentals present substantial downside potential for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →